<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03569826</url>
  </required_header>
  <id_info>
    <org_study_id>CAPCR ID: 18-5951</org_study_id>
    <nct_id>NCT03569826</nct_id>
  </id_info>
  <brief_title>Canadian Network for Autoimmune Liver Disease</brief_title>
  <acronym>CaNAL</acronym>
  <official_title>Canadian Network for Autoimmune Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      CaNAL is a longitudinal observational cohort study of patients diagnosed with Primary Biliary&#xD;
      Cholangitis (PBC), Autoimmune Hepatitis (AIH), or overlap syndrome. This study creates a&#xD;
      nationwide registry and network focusing on high quality long-term follow-up of individual&#xD;
      patient data from major Canadian centers.&#xD;
&#xD;
      Primary Biliary Cholangitis (PBC) and Autoimmune Hepatitis (AIH) are rare and slowly&#xD;
      progressive liver diseases associated with development of cirrhosis, liver cancer (HCC) and&#xD;
      liver failure requiring liver transplantation or leading to premature death. The rarity and&#xD;
      slowly progressive nature of these autoimmune liver diseases make them difficult to study and&#xD;
      only a large scale approach combining patient data from multiple centers across Canada will&#xD;
      allow new insights. The primary aim of the Canadian Network for Autoimmune Liver Disease is&#xD;
      to build a Canadian registry of patients with PBC, AIH, and overlap syndrome. We capture&#xD;
      patient characteristics, laboratory assessments and natural history, patient-reported&#xD;
      outcomes including quality of life measures and environmental exposures, response to&#xD;
      treatment, and pre- and post-transplant outcomes. We will then identify risk factors&#xD;
      associated with critical outcomes for the patient, including response to treatment,&#xD;
      progression to transplant, risk of liver cancer, and recurrent disease after transplant. We&#xD;
      can identify biomarkers (biochemical indicators of progression of disease) to help diagnose&#xD;
      autoimmune liver disease at its earliest stages, ensuring timely treatment and preventing&#xD;
      disease progression. CaNAL will provide a better understanding of autoimmune liver diseases,&#xD;
      biomarkers predictive of disease progression or non-response to therapy as well as better&#xD;
      knowledge of the etiology and pathogenesis. CaNAL will also help to serve as a platform for&#xD;
      conducting clinical trials or targeted lab-studies to answer important questions that are&#xD;
      unlikely to be evaluated by the pharmaceutical industry.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 7, 2018</start_date>
  <completion_date type="Anticipated">December 2028</completion_date>
  <primary_completion_date type="Anticipated">December 2028</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>6 Years</target_duration>
  <primary_outcome>
    <measure>Liver transplant-free survival over time</measure>
    <time_frame>Up to 6 years or time of death/liver transplant</time_frame>
    <description>Time-to-event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical values over time (e.g. aspartate aminotransferase, alkaline phosphatase, alanine aminotransferase, Bilirubin)</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>Investigate trends of different biochemical values over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form 36 (SF-36)</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>Health-Related Quality of Life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PBC-40</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>Health-Related Quality of Life, specific to Primary Biliary Cholangitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5D Pruritus Scale</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>Itch-Related Quality of Life through 5 dimensions: duration, degree, direction, disability, and distribution. Each dimension is scored from 1(lowest) to 5(highest) for a total score range of 5-25</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Itch Visual Analog Scale</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>Itch-Related Quality of Life; Continuous unitless itch scale from no itch to worst itch imaginable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Itch Numeric Rating Scale</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>Itch-Related Quality of Life; Categorical integer scale from 0 (no itch) to 10 (worst itch imaginable)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Primary Bilary Cirrhosis (PBC)</condition>
  <condition>Autoimmune Hepatitis</condition>
  <condition>Overlap Syndrome</condition>
  <arm_group>
    <arm_group_label>Observational</arm_group_label>
    <description>There is no intervention being administered. This registry only observes patients through their regular standard of care visits.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational; no intervention</intervention_name>
    <description>Observational; no intervention</description>
    <arm_group_label>Observational</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a diagnosis of Primary Biliary Cholangitis and/or Autoimmune Hepatitis across&#xD;
        Canada.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Primary Biliary Cholangitis and/or Autoimmune Hepatitis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Less than 18 years of age&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bettina Hansen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Mason, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Surain Roberts, AB</last_name>
    <phone>613 291 5039</phone>
    <email>surain.roberts@uhn.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kattleya Tirona, BA, CCRP</last_name>
    <phone>416 340 4800</phone>
    <phone_ext>6912</phone_ext>
    <email>kattleya.tirona@uhn.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Swain, MD</last_name>
      <phone>403-944-6514</phone>
      <email>swain@ucalgary.ca</email>
    </contact>
    <investigator>
      <last_name>Mark Swain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Mason, MD</last_name>
      <phone>780-492-8176</phone>
      <email>am16@ualberta.ca</email>
    </contact>
    <contact_backup>
      <last_name>Ellina Lytvyak</last_name>
      <email>lytvyak@ualberta.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Andrew Mason, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aldo Montano-Loza, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric M Yoshida, MD</last_name>
      <phone>604-875-5371</phone>
      <email>eric.yoshida@vch.ca</email>
    </contact>
    <investigator>
      <last_name>Eric M Yoshida, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hin Hin Ko, MD</last_name>
      <phone>604-688-6332</phone>
    </contact>
    <investigator>
      <last_name>Hin Hin Ko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Health Sciences Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nabiha Faisal, MD</last_name>
      <phone>204-789-3650</phone>
      <email>Nabiha.Faisal@umanitoba.ca</email>
    </contact>
    <investigator>
      <last_name>Nabiha Faisal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>McMaster University Medical Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8S 4K1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marco Puglia, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marco Puglia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kingston Health Sciences Centre (HDH Site)</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5G2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre - University Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karim Qumosani, MD</last_name>
      <phone>519-663-3976</phone>
      <email>Karim.Qumosani@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Karim Qumosani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Cheung, MD</last_name>
      <phone>613-737-8899</phone>
      <phone_ext>73224</phone_ext>
      <email>angcheung@toh.ca</email>
    </contact>
    <contact_backup>
      <last_name>Miriam Muir</last_name>
      <email>mmuir@toh.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Angela Cheung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bettina Hansen, PhD</last_name>
      <phone>416-340-5157</phone>
      <email>bettina.hansen@utoronto.ca</email>
    </contact>
    <contact_backup>
      <last_name>Kattleya Tirona</last_name>
      <email>kattleya.tirona@uhn.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Bettina Hansen, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McMaster University Medical Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc Deschenes</last_name>
    </contact>
    <contact_backup>
      <last_name>Hansi Peiris</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>76159</phone_ext>
      <email>hansi.peiris@muhc.mcgill.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Marc Deschenes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Vincent, MD</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>35705</phone_ext>
      <email>catherine.vincent@umontreal.ca</email>
    </contact>
    <investigator>
      <last_name>Catherine Vincent, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Université de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1G2E8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dusanka Grbic</last_name>
      <phone>819-346-1110</phone>
      <email>Dusanka.Grbic@usherbrooke.ca</email>
    </contact>
    <contact_backup>
      <last_name>Chantal Guillet</last_name>
      <phone>819-346-1110</phone>
      <phone_ext>12821</phone_ext>
      <email>chantal.guillet.ciussse-chus@ssss.gouv.qc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Dusanka Grbic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal University Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lawrence Worobetz, MD</last_name>
      <phone>306-966-7964</phone>
      <email>worobetz@sasktel.net</email>
    </contact>
    <investigator>
      <last_name>Lawrence Worobetz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 25, 2018</study_first_submitted>
  <study_first_submitted_qc>June 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2018</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Hepatitis, Autoimmune</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Patient data will be anonymized. A standardized electronic case record (e-CRF) form will be used to capture the data. The e-CRF form has been designed in REDCap, a secure web based application supporting data capture for research studies. REDCap is designed to comply with HIPAA security regulations. The CaNAL REDCap database (REDCap project CaNAL) has been established at the University of Alberta under the jurisdiction of the Women and Children's Health Research Institute (WCHRI).&#xD;
Individual centres will have access only to their own data and patient identifiers will only be visible to the individual centres. The steering committee will have access to all anonymized data within the REDCap database, that is without any patient identifiers. Main centres in Toronto and Edmonton will have access to de-identified data.&#xD;
Results will be disseminated via publication in international literature and presentation at international liver conferences. Patient data will be anonymous.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 27, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT03569826/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

